The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Previous

8 Early Symptoms: Could You Have Hepatitis C?

Back to News Homepage

Next

Key Outcome of HCV Trial: BIT225 Was Safe and Well-Tolerated

Drug Candidate Emricasan to Stop Progression of Liver Disease

March 3, 2016

Print this page

Learn how Emricasan, a first-in-class, orally active caspase protease inhibitor, offers the untapped medical need to stop liver fibrosis, nonalcoholic steatohepatitis (NASH) and cirrhosis.

San Diego-based Conatus takes aim at unmet medical need in cirrhosis

By Nicole Gray | March 2, 2016 Print

The approval of Gilead’s Sovaldi in December 2013 for oral treatment of hepatitis C (HCV) represented a major medical breakthrough. Not only did it provide HCV-infected patients with a vastly more effective treatment option than traditional interferon-based therapies, but Sovaldi was also curative in many cases.

The HCV market has only expanded since then as Gilead introduced Harvoni, followed by AbbVie’s VieKira Pak and Merck’s new drug Zepatier.

Continue reading this entire article:
http://www.biopharmadive.com/news/san-diego-based-conatus-takes-aim-at-unmet-medical-need-in-cirrhosis/414898/

1 Comment
Share
Share

Previous

8 Early Symptoms: Could You Have Hepatitis C?

Back to News Homepage

Next

Key Outcome of HCV Trial: BIT225 Was Safe and Well-Tolerated

Requirements for using and reposting articles

Comments

HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.

  • dsiple

    Where can I sign up?